These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 3103161)

  • 21. Serotonin and the mammalian circadian system: I. In vitro phase shifts by serotonergic agonists and antagonists.
    Prosser RA; Dean RR; Edgar DM; Heller HC; Miller JD
    J Biol Rhythms; 1993; 8(1):1-16. PubMed ID: 8490207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mediation of the discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) by the putative 5-HT1A receptor.
    Tricklebank MD; Neill J; Kidd EJ; Fozard JR
    Eur J Pharmacol; 1987 Jan; 133(1):47-56. PubMed ID: 2881789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of the discriminative stimulus properties of cocaine by 5-HT1B and 5-HT2C receptors.
    Callahan PM; Cunningham KA
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1414-24. PubMed ID: 7562516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of repeated administration of the monoamine oxidase inhibitor phenelzine on the discriminability of d-lysergic acid diethylamide (LSD) and 1-(m-trifluoromethylphenyl) piperazine (TFMPP).
    Cunningham KA; Carroll BA; Appel JB
    Psychopharmacology (Berl); 1986; 89(1):134-5. PubMed ID: 3090587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ; Aghajanian GK
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LSD, 5-HT (serotonin), and the evolution of a behavioral assay.
    Appel JB; West WB; Buggy J
    Neurosci Biobehav Rev; 2004 Jan; 27(8):693-701. PubMed ID: 15019419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discriminative stimulus properties of lysergic acid diethylamide in the monkey.
    Nielsen EB
    J Pharmacol Exp Ther; 1985 Jul; 234(1):244-9. PubMed ID: 4009503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide.
    Burris KD; Sanders-Bush E
    Mol Pharmacol; 1992 Nov; 42(5):826-30. PubMed ID: 1359397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discriminative-stimulus effects of quipazine and l-5-hydroxytryptophan in relation to serotonin binding sites in the pigeon.
    Walker EA; Yamamoto T; Hollingsworth PJ; Smith CB; Woods JH
    J Pharmacol Exp Ther; 1991 Nov; 259(2):772-82. PubMed ID: 1941625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differentiation between the stimulus effects of l-5-hydroxytryptophan and LSD.
    Cunningham KA; Callahan PM; Appel JB
    Eur J Pharmacol; 1985 Jan; 108(2):179-86. PubMed ID: 3156756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
    Marona-Lewicka D; Thisted RA; Nichols DE
    Psychopharmacology (Berl); 2005 Jul; 180(3):427-35. PubMed ID: 15723230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
    Kleven MS; Assié MB; Koek W
    J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amphetamine and LSD as discriminative stimuli: alterations following neonatal monoamine reductions.
    Minnema DJ; Rosecrans JA
    Pharmacol Biochem Behav; 1984 Jan; 20(1):95-101. PubMed ID: 6420809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
    Pierce PA; Peroutka SJ
    J Pharmacol Exp Ther; 1988 Dec; 247(3):918-25. PubMed ID: 3204523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discriminative stimulus properties of indorenate, a 5-HT1A, 5-HT1B and 5-HT2C agonist: a study in rats.
    Sánchez H; Velázquez-Martínez DN
    J Psychopharmacol; 2001 Mar; 15(1):29-36. PubMed ID: 11277605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. D-16949 (anpirtoline): a novel serotonergic (5-HT1B) psychotherapeutic agent assessed by its discriminative effects in the rat.
    Swedberg MD; Shannon HE; Nickel B; Goldberg SR
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1015-22. PubMed ID: 1335050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
    Buckholtz NS; Zhou DF; Freedman DX; Potter WZ
    Neuropsychopharmacology; 1990 Apr; 3(2):137-48. PubMed ID: 1969270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats.
    Krebs KM; Geyer MA
    Psychopharmacology (Berl); 1994 Jan; 113(3-4):429-37. PubMed ID: 7862855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions.
    White FJ; Appel JB
    Science; 1982 Apr; 216(4545):535-7. PubMed ID: 7071600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of agonists, partial agonists, and antagonists on the regulation of 5-hydroxytryptamine2 receptors in P11 cells.
    Ferry RC; Unsworth CD; Molinoff PB
    Mol Pharmacol; 1993 May; 43(5):726-33. PubMed ID: 8388988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.